Neoadjuvant Inituomab, Pyrrolidone and Nab-paclitaxel for HER2+Breast Cancer
Clinical trial NCT05444998 · UNKNOWN
Trial details
- NCT number
- NCT05444998
- Sponsor
- Xijing Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-11-01
- Primary completion
- 2023-08-31
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.